Responses
Scientific Abstracts
Poster Presentations
Posters
Rheumatoid arthritis – anti-TNF therapy
SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn’s disease
Compose a Response to This Article
Other responses
No responses have been published for this article.